Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cladribine and Rituximab Variant #01 | — | R 48 077 | 21d | — | — | ~6 | ~R 288 462 indirect | — |
Cladribine monotherapy Variant #03 | — | R 34 921 | 35d | — | — | ~1 | ~R 34 921 indirect | — |
Interferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | ~5.4 mo | ~17.5 mo | ~2 | — | 10 |
Pentostatin monotherapy Variant #01 Partial | — | — | 14d | — | — | ~1 | — | — |
4 of 4 regimens shown